IOVANCE BIOTHERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | — | — |
| Operating income | -$403.4M | -$395.3M | -$460.6M | -$398.9M | -$342.7M |
| Operating expenses | — | — | — | $398.9M | $342.7M |
| Cost of revenue | $173.2M | $93.2M | $1.0M | — | — |
| Cash from operations | -$302.4M | -$353.0M | -$361.8M | -$292.8M | -$227.9M |
| Capital expenditure | $33.8M | $11.1M | $22.3M | $20.4M | $37.6M |
| Free cash flow | -$336.2M | -$364.0M | -$384.1M | -$313.2M | -$265.5M |
| Impairments | — | $7.4M | — | $397,000 | $0 |
| Total assets | $913.2M | $910.4M | $780.4M | $664.0M | $777.3M |
| Total liabilities | $214.6M | $200.0M | $195.7M | $164.3M | $155.7M |
Shares outstanding 446.5M · Free float 84.4%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.